青蒿素原料生产与资源再生全球战略研究

发布时间：2018-05-16 00:16

本文选题：青蒿素 + 黄花蒿　；参考：《科学通报》2017年18期

【摘要】：青蒿素被世界卫生组织推选为抗疟一线药物,中药青蒿原植物黄花蒿(Artemisia annua L.)是青蒿素的主要来源.然而,全球范围内黄花蒿青蒿素含量差异较大,大部分地区野生资源无工业提取价值.本文从全球视角对黄花蒿分布与产地适宜性、引种栽培等青蒿素资源再生进行了分析与阐述,并对原料提取工艺、生物合成和化学合成进行综合分析.通过研究及分析发现,高青蒿素含量黄花蒿生态适宜区主要在中国秦岭-淮河分界线以南,面积1.54×10~6 km~2,占全球分布的77.08%.巴西和美国也有少量分布,面积分别为1.49×10~6 km~2(7.43%)和1.30×10~6 km~2(6.47%).越南和日本有零星分布.优质黄花蒿生态次适宜区包括亚洲东南部、欧洲西部、北美洲南部与南美洲中部.通过黄花蒿新品种培育和规范化栽培可显著提高青蒿素含量.青蒿素资源再生与原料生产为"一带一路"走出去的全球中药资源国家战略实施奠定基础.
[Abstract]:Artemisinin was selected by the World Health Organization as a first-line antimalarial drug, Artemisia annua L. Is the main source of artemisinin. However, artemisinin content of Artemisia annua varies greatly in the world, and there is no industrial extraction value of wild resources in most areas. In this paper, artemisinin resources regeneration of Artemisia annua L. from the global perspective, such as distribution and suitability of producing area, introduction and cultivation, were analyzed and expounded, and the extraction process, biosynthesis and chemical synthesis of raw materials were comprehensively analyzed. It is found that the ecological suitable area of Artemisia annua with high artemisinin content is mainly in the south of Qinling-Huaihe River demarcation line in China, with an area of 1.54 脳 10 ~ (6) km ~ (-2), accounting for 77.08% of the global distribution. There is also a small distribution in Brazil and the United States, with an area of 1.49 脳 10 ~ (6) km ~ (2) and 1.30 脳 10 ~ (6) km ~ (2) ~ (2) ~ 6.47, respectively. Vietnam and Japan are scattered. Good quality Artemisia annua ecological sub-suitable areas include southeast Asia, western Europe, southern North America and central South America. The artemisinin content can be significantly increased by cultivation and standardized cultivation of new varieties of Artemisia annua. The regeneration of artemisinin resources and the production of raw materials lay the foundation for the implementation of the national strategy of "Belt and Road".
【作者单位】：中国中医科学院中药研究所北京市中药鉴定与安全性检测评估重点实验室;中国医学科学院北京协和医学院药用植物研究所;
【基金】：中国科学院科技服务网络计划(STS计划)(KFJ-EW-STS-074);中国科学院战略先导科技专项(B类)(XDB03030100) 国家自然科学基金重大项目(41190081) “第三极环境(TPE)”国际计划资助
【分类号】：R284;S567.219

【参考文献】